EPISODE · May 29, 2026 · 7 MIN
When Pharma Patents Expire How Pfizer Is Handling the Cliff
from The Investing Podcast with Fexingo: Stocks, Bonds, and Building a Long-Term Portfolio · host Fexingo
Pfizer has seen its stock languish near $26 after the Covid revenue boom faded. But with a $1.2 trillion weight-loss drug market opening and patent expirations looming, the company is at a strategic crossroads. Lucas and Luna examine Pfizer's pipeline bets, the math on its dividend yield, and what the 'patent cliff' really means for long-term investors. They reference the latest CPI data showing persistent inflation and discuss how pharma stocks fit into a portfolio when big pharma is out of favor. #Pfizer #PatentCliff #PharmaStocks #DividendYield #WeightLossDrugs #GLP1 #Inflation #CPI #PortfolioStrategy #ValueInvesting #BigPharma #DrugPricing #Finance #Investing #FexingoBusiness #BusinessPodcast #TheInvestingPodcast #LongTermInvesting Keep every episode free: buymeacoffee.com/fexingo
What this episode covers
Pfizer has seen its stock languish near $26 after the Covid revenue boom faded. But with a $1.2 trillion weight-loss drug market opening and patent expirations looming, the company is at a strategic crossroads. Lucas and Luna examine Pfizer's pipeline bets, the math on its dividend yield, and what the 'patent cliff' really means for long-term investors. They reference the latest CPI data showing persistent inflation and discuss how pharma stocks fit into a portfolio when big pharma is out of favor. #Pfizer #PatentCliff #PharmaStocks #DividendYield #WeightLossDrugs #GLP1 #Inflation #CPI #PortfolioStrategy #ValueInvesting #BigPharma #DrugPricing #Finance #Investing #FexingoBusiness #BusinessPodcast #TheInvestingPodcast #LongTermInvesting Keep every episode free: buymeacoffee.com/fexingo
NOW PLAYING
When Pharma Patents Expire How Pfizer Is Handling the Cliff
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.